Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

被引:8
|
作者
Lopez-Medrano, Francisco [1 ,3 ]
Asin, Maria Asuncion Perez-Jacoiste [1 ]
Fernandez-Ruiz, Mario [1 ]
Carretero, Octavio [1 ]
Lalueza, Antonio [3 ]
Maestro de la Calle, Guillermo [3 ]
Manuel Caro, Jose [4 ]
de la Calle, Cristina [3 ]
Catalan, Mercedes [5 ]
Garcia-Garcia, Rocio [6 ]
Martinez-Lopez, Joaquin [2 ,7 ]
Origuen, Julia [8 ]
Ripoll, Mar [3 ]
San Juan, Rafael [1 ,2 ]
Trujillo, Hernando [9 ]
Sevillano, Angel [9 ]
Gutierrez, Eduardo [9 ]
de Miguel, Borja [3 ]
Aguilar, Fernando [3 ]
Gomez, Carlos [10 ]
Silva, Jose Tiago [1 ]
Garcia-Ruiz De Morales, Daniel [1 ]
Saro-Buendia, Miguel [1 ]
Marrero-Sanchez, Angel [1 ]
Chiara-Graciani, Guillermo [1 ]
Bueno, Hector [11 ]
Paz-Artal, Estela [12 ]
Lumbreras, Carlos [2 ,3 ]
Pablos, Jose L. [2 ,13 ]
Maria Aguado, Jose [1 ,2 ]
机构
[1] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Internal Med, Unit Infect Dis, Madrid, Spain
[2] Univ Complutense Madrid, Sch Med, Dept Med, Madrid, Spain
[3] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Internal Med, Madrid, Spain
[4] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Pharm, Madrid, Spain
[5] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Intens Care Med, Madrid, Spain
[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Pneumol, Madrid, Spain
[7] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Hematol, Madrid, Spain
[8] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Emergency Med, Madrid, Spain
[9] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Nephrol, Madrid, Spain
[10] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Oncol, Madrid, Spain
[11] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Cardiol, Madrid, Spain
[12] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Immunol, Madrid, Spain
[13] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Rheumatol, Madrid, Spain
关键词
COVID-19; SARS-CoV-2; Tocilizumab; Corticosteroids; Therapy; Immunomodulation; Outcome; Mortality; RESPIRATORY-DISTRESS-SYNDROME; CYTOKINE STORM; HYPERINFLAMMATION; MULTICENTER; BLOCKADE;
D O I
10.1016/j.ijid.2021.02.099
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The role of combination immunomodulatory therapy with systemic corticosteroids and tocilizumab (TCZ) for aged patients with COVID-19-associated cytokine release syndrome remains unclear. Methods: A retrospective single-center study was conducted on consecutive patients aged >65 years who developed severe COVID-19 between 03 March and 01 May 2020 and were treated with corticosteroids at various doses (methylprednisolone 0.5 mg/kg/12 h to 250 mg/24 h), either alone (CS group) or associated with intravenous tocilizumab (400?600 mg, one to three doses) (CS-TCZ group). The primary outcome was all-cause mortality by day +14, whereas secondary outcomes included mortality by day +28 and clinical improvement (discharge and/or a >2 point decrease on a 6-point ordinal scale) by day +14. Propensity score (PS)-based adjustment and inverse probability of treatment weights (IPTW) were applied. Results: Totals of 181 and 80 patients were included in the CS and CS-TCZ groups, respectively. All-cause 14day mortality was lower in the CS-TCZ group, both in the PS-adjusted (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.17?0.68; P = 0.002) and IPTW-weighted models (odds ratio [OR]: 0.38; 95% CI: 0.21?0.68; P = 0.001). This protective effect was also observed for 28-day mortality (PS-adjusted HR: 0.38; 95% CI: 0.21?0.72; P = 0.003). Clinical improvement by day +14 was higher in the CS-TCZ group with IPTW analysis only (OR: 2.26; 95% CI: 1.49?3.41; P < 0.001). The occurrence of secondary infection was similar between both groups. Conclusions: The combination of corticosteroids and TCZ was associated with better outcomes among patients aged >65 years with severe COVID-19. ? 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [31] Steroid Pulse Therapy as a Treatment for Patients With COVID-19 Pneumonia at an Intensive Care Unit: A Single-Center Retrospective Observational Study
    Okano, Hiromu
    Sakurai, Ryota
    Yamazaki, Tsutomu
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [32] Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study
    Abdelnaby, Hassan
    Aboelhassan, Wael
    Al-Jarallah, Mohammed
    Rajan, Rajesh
    Dashti, Raja
    Zhanna, Kobalava D.
    Alsaber, Ahmad R.
    Abd el-Aleem, Ahmed
    Ashry, Islam
    Abdullah, Mohammed
    Mahmoud Fouad, Ahmed
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2021, 26 (12) : 1689 - 1699
  • [33] A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
    Yin Wang
    Weiwei Jiang
    Qi He
    Cheng Wang
    Baoju Wang
    Pan Zhou
    Nianguo Dong
    Qiaoxia Tong
    [J]. Signal Transduction and Targeted Therapy, 5
  • [34] A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
    Wang, Yin
    Jiang, Weiwei
    He, Qi
    Wang, Cheng
    Wang, Baoju
    Zhou, Pan
    Dong, Nianguo
    Tong, Qiaoxia
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [35] Clinical presentation of severe COVID-19 with heart failure: A single-center retrospective study
    Liu, Xinling
    Liu, Tingting
    Wan, Rong
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2024, 27 (05)
  • [36] Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study
    Kewan, Tariq
    Covut, Fahrettin
    Al-Jaghbeer, Mohammed J.
    Rose, Lori
    Gopalakrishna, K., V
    Akbik, Bassel
    [J]. ECLINICALMEDICINE, 2020, 24
  • [37] Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
    Yurttutan, Sadik
    Gullu, Utku Ufuk
    Ipek, Sevcan
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (04) : 1101 - 1103
  • [38] Pediatric Patients with COVID-19: A Retrospective Single-Center Experience
    Sahin, Ayse
    Dalgic, Nazan
    Sancar, Mesut
    Congur, Emel Celebi
    Kanik, Mehmet Kemal
    Ilgar, Sibel Degim
    Bayraktar, Banu
    Ozdemir, Haci Mustafa
    [J]. MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2022, 56 (01): : 62 - 69
  • [39] Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
    Aomar-Millan, Ismael Francisco
    Salvatierra, Juan
    Hernandez-Quero, Jose
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (04) : 1105 - 1106
  • [40] PROFILE OF PATIENTS DIAGNOSED WITH COVID-19 INFECTION: A SINGLE-CENTER RETROSPECTIVE STUDY
    Wegrzynek-Gallina, Julia
    Pilsniak, Joanna
    Pilsniak, Aleksandra
    Jarosinska, Agnieszka
    Pietrukaniec, Marta
    Holecki, Michal
    [J]. HEALTH PROBLEMS OF CIVILIZATION, 2024, 18 (02) : 180 - 193